电邮这篇文章 Clinical and immunological criteria for the use of intravenous immunoglobulins in women with reproductive failures
- 作者: Agnaeva A.O.1, Bespalova O.N.1, Sokolov D.I.1, Mikhailova V.A.1, Chepanov S.V.1, Selkov S.A.1, Kogan I.Y.1
-
隶属关系:
- The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
- 期: 卷 72, 编号 4 (2023)
- 页面: 37-46
- 栏目: Original Research
- URL: https://journals.eco-vector.com/jowd/article/view/202790
- DOI: https://doi.org/10.17816/JOWD202790
- ID: 202790
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
BACKGROUND: In obstetrics and reproductive medicine, the use of intravenous immunoglobulin remains controversial. There are no clearly developed indications for immunoglobulins therapy. The search for immunological criteria for prescribing this therapy is an urgent task
AIM: The aim of this study was to evaluate the effectiveness of the use of intravenous immunoglobulins in the complex therapy of women with multiple reproductive losses associated with changes in the quantitative and functional parameters of natural killer cells.
MATERIALS AND METHODS: Group 1 consisted of 61 women with recurrent miscarriage; group 2 involved 40 women with two or more in vitro fertilization failures, while group 3 comprised 27 healthy fertile individuals. The activity of blood natural killer cells was assessed by CD107a expression before and after activation. Patients with altered natural killer cell activity received intravenous immunoglobulins therapy under the control of the dynamics of immunological parameters.
RESULTS: The number of natural killer cells that expressed CD107a before and after activation differed between the study groups. In patients receiving intravenous immunoglobulins, gestational complications were observed less frequently, with the incidence of biochemical pregnancy being higher.
CONCLUSIONS: In patients with early reproductive failures (such as recurrent miscarriage and in vitro fertilization failures) and immunological abnormalities in the form of altered Natural killer cell activity, the use of intravenous immunoglobulins has an immunomodulatory and clinical effect.
全文:
作者简介
Alana Agnaeva
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: dr.agnaeva@gmail.com
ORCID iD: 0000-0001-8978-3221
SPIN 代码: 1130-8280
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgOlesya Bespalova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: shiggerra@mail.ru
ORCID iD: 0000-0002-6542-5953
SPIN 代码: 4732-8089
Scopus 作者 ID: 57189999252
Researcher ID: D-3880-2018
MD, Dr. Sci. (Med.)
俄罗斯联邦, Saint PetersburgDmitry Sokolov
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: falcojugger@yandex.ru
ORCID iD: 0000-0002-5749-2531
SPIN 代码: 3746-0000
Scopus 作者 ID: 14020604500
Researcher ID: E-9050-2014
Dr. Sci. (Biol.)
俄罗斯联邦, Saint PetersburgValentina Mikhailova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: mva_spb@mail.ru
ORCID iD: 0000-0003-1328-8157
SPIN 代码: 1749-5100
Scopus 作者 ID: 55598998100
Researcher ID: L-3245-2015
Cand. Sci. (Biol.)
俄罗斯联邦, Saint PetersburgSergey Chepanov
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
编辑信件的主要联系方式.
Email: chepanovsv@gmail.com
ORCID iD: 0000-0001-6087-7152
SPIN 代码: 6642-6837
Scopus 作者 ID: 56399329700
Researcher ID: M-3471-2015
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgSergey Selkov
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: selkovsa@mail.ru
ORCID iD: 0000-0003-1560-7529
SPIN 代码: 7665-0594
Scopus 作者 ID: 6507854443
Researcher ID: G-2059-2014
MD, Dr. Sci. (Med.), Professor, Honored Scientist of the Russian Federation
俄罗斯联邦, Saint PetersburgIgor Kogan
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: ikogan@mail.ru
ORCID iD: 0000-0002-7351-6900
SPIN 代码: 6572-6450
Scopus 作者 ID: 56895765600
Researcher ID: P-4357-2017
MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences
俄罗斯联邦, Saint Petersburg参考
- Recurrent pregnancy loss: causes, controversies and treatment. Ed. by H. Carp. New York: CRC Press; 2000. doi: 10.1201/9780429450303
- Makrigiannakis A, Petsas G, Toth B, et al. Recent advances in understanding immunology of reproductive failure. J Reprod Immunol. 2011;90(1):96–104. doi: 10.1016/j.jri.2011.03.006
- Bashiri A, Halper KI, Orvieto R. Recurrent implantation failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;16(1). doi: 10.1186/s12958-018-0414-2
- Coughlan C, Ledger W, Wang Q, et al. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014;28(1):14–38. doi: 10.1016/j.rbmo.2013.08.011
- Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol. 2019;221(5):437–456. doi: 10.1016/j.ajog.2019.05.044
- Kwak-Kim J, Sung N, Saab W, et al. Introduction of the special issue, “Clinical reproductive immunology”. Am J Reprod Immunol. 2021;85(4). doi: 10.1111/aji.13415
- Koopman LA, Kopcow HD, Rybalov B, et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med. 2003;198(8):1201–1212. doi: 10.1084/jem.20030305
- Beer AE, Kwak JY, Ruiz JE. Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles. Am J Reprod Immunol. 1996;35(4):376–382. doi: 10.1111/j.1600-0897.1996.tb00497.x
- Sacks G, Yang Y, Gowen E, et al. Detailed analysis of peripheral blood natural killer cells in women with repeated IVF failure. Am J Reprod Immunol. 2012;67(5):434–442. doi: 10.1111/j.1600-0897.2012.01105.x
- Perricone C, De Carolis C, Giacomelli R, et al. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology (Oxford). 2007;46(10):1574–1578. doi: 10.1093/rheumatology/kem197
- Recurrent pregnancy loss evidence-based evaluation, diagnosis and treatment. Ed. by A. Bashiri, A. Harlev, A. Agarwal. New York: Springer International Publishing; 2016. doi: 10.1007/978-3-319-27452-2
- Tang AW, Alfirevic Z, Quenby S. Natural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review. Hum Reprod. 2011;26(8):1971–1980. doi: 10.1093/humrep/der164
- Seshadri S, Sunkara SK. Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(3):429–438. doi: 10.1093/humupd/dmt056
- Ushkalova EA, Shifman EM. A problem in the unregulated use of intravenous immunoglobulin in obstetrics. Obstetrics and Gynecology. 2011;(3):74–80. (In Russ.)
- Stephenson MD, Fluker MR. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial. Fertil Steril. 2000;74(6):1108–1113. doi: 10.1016/s0015-0282(00)01622-8
- Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2006;(2). doi: 10.1002/14651858.CD000112.pub2
- Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2014;2014(10). doi: 10.1002/14651858.CD000112.pub3
- Saab W, Seshadri S, Huang C, et al. A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses. Am J Reprod Immunol. 2021;85(4). doi: 10.1111/aji.13395
- Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG. 2007;114(2):134–142. doi: 10.1111/j.1471-0528.2006.01201.x
- Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol. 2012;67(4):296–304. doi: 10.1111/j.1600-0897.2012.01111.x
- Achilli C, Duran-Retamal M, Saab W, et al. The role of immunotherapy in in vitro fertilization and recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2018;110(6):1089–1100. doi: 10.1016/j.fertnstert.2018.07.004
- Graphou O, Chioti A, Pantazi A, et al. Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am J Reprod Immunol. 2003;49(1):21–29. doi: 10.1034/j.1600-0897.2003.01169.x
- Chugunova AA, Zainulina MS, Selutin AV, et al. The influence of immunomodulating therapy on clinical and laboratory results in pregnant women with antiphopholipid syndrome and recurrent pregnancy loss. Journal of Obstetrics and Women’s Diseases. 2011;(3):152–160. (In Russ.)
- Ahmadi M, Ghaebi M, Abdolmohammadi-Vahid S, et al. NK cell frequency and cytotoxicity in correlation to pregnancy outcome and response to IVIG therapy among women with recurrent pregnancy loss. J Cell Physiol. 2019;234(6):9428–9437. doi: 10.1002/jcp.27627
- Reed JL, Winger EE. IVIg therapy increases delivery birthweight in babies born to women with elevated preconception proportion of peripheral blood (CD56+/CD3–) natural killer cells. Clin Exp Obstet Gynecol. 2017;44(3):384–391.
- Lash GE, Otun HA, Innes BA, et al. Interferon-gamma inhibits extravillous trophoblast cell invasion by a mechanism that involves both changes in apoptosis and protease levels. FASEB J. 2006;20(14):2512–2518. doi: 10.1096/fj.06-6616com
- Uterine endometrial function. Ed. by H. Kanzaki. Osaka: Springer Japan; 2016. doi: 10.1007/978-4-431-55972-6
- Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11(7):615–628. doi: 10.1593/neo.09284
- Horton NC, Mathew PA. NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front Immunol. 2015;6. doi: 10.3389/fimmu.2015.00031
- Tao Y, Li YH, Piao HL, et al. CD56(bright)CD25+ NK cells are preferentially recruited to the maternal/fetal interface in early human pregnancy. Cell Mol Immunol. 2015;12(1):77–86. doi: 10.1038/cmi.2014.26
补充文件
